These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3318450)

  • 1. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.
    Blane GF
    Am J Med; 1987 Nov; 83(5B):26-36. PubMed ID: 3318450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of European clinical experience with fenofibrate.
    Blane GF
    Cardiology; 1989; 76 Suppl 1():1-10; discussion 10-3. PubMed ID: 2653620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of fenofibrate--US and worldwide experience.
    Roberts WC
    Cardiology; 1989; 76(3):169-79. PubMed ID: 2673510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
    Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
    Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fibric acid derivatives on biliary lipid composition.
    Palmer RH
    Am J Med; 1987 Nov; 83(5B):37-43. PubMed ID: 3318452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
    Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J
    Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
    Balfour JA; McTavish D; Heel RC
    Drugs; 1990 Aug; 40(2):260-90. PubMed ID: 2226216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate in type IV and type V hyperlipoproteinemia.
    Seidehamel RJ
    Cardiology; 1989; 76 Suppl 1():23-8; discussion 29-32. PubMed ID: 2653622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
    Bastow MD; Durrington PN; Ishola M
    Metabolism; 1988 Mar; 37(3):217-20. PubMed ID: 3278190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate affects the compositions of lipoproteins.
    Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
    Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia.
    Podda M; Zuin M
    Atherosclerosis; 1985 May; 55(2):135-42. PubMed ID: 4004987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.
    Ginsberg HN
    Am J Med; 1987 Nov; 83(5B):66-70. PubMed ID: 3318456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the effects of fenofibrate on lipoproteins, apoproteins, and bile saturation: US studies.
    Knopp RH
    Cardiology; 1989; 76 Suppl 1():14-22; discussion 29-32. PubMed ID: 2653621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice.
    Ujházy E; Onderová E; Horáková M; Bencová E; Durisová M; Nosál R; Balonová T; Zeljenková D
    Pharmacol Toxicol; 1989 Mar; 64(3):286-90. PubMed ID: 2726692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.